Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.

@article{Zeymer2010RandomizedCO,
  title={Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.},
  author={Uwe Zeymer and Alain Margenet and Michael Haude and Christoph Bode and J. M. Lablanche and H. Heuer and Rolf Schr{\"o}der and Stefan S Kropff and Ryad Bourkaib and Norbert Banik and Ralf Zahn and Emmanuel Teiger},
  journal={Journal of the American College of Cardiology},
  year={2010},
  volume={56 6},
  pages={463-9}
}
OBJECTIVES The aim of this study was to compare eptifibatide and abciximab as adjuncts to primary percutaneous coronary intervention (PCI). BACKGROUND The glycoprotein (GP) IIb/IIIa receptor inhibitor abciximab as adjunct to primary PCI in patients with ST-segment elevation myocardial infarctions has been shown to reduce ischemic complications and improve clinical outcomes. So far, no trial has been performed to compare the efficacy of another GP IIb/IIIa receptor inhibitor, eptifibatide, and… CONTINUE READING